【摘要】 急性髓系白血病（AML）是一类起源于造血干/祖细胞累积性遗传变异的血液恶性肿瘤，在成人中较常见，发病率和死亡率高。由于AML具有高度的遗传异质性，整体治疗预后不容乐观。随着高通量测序技术的发展，表观遗传变异被揭示是驱动AML发生的关键遗传因素，组蛋白乙酰化修饰失衡是其中的一大类。近年来，针对组蛋白乙酰化修饰调控的特定抑制剂进行靶向治疗被广泛应用与研究，在包括AML在内的各种肿瘤的发生和干预中扮演着不可忽视的角色。鉴于此，本文概述了当前组蛋白乙酰化修饰在AML发生发展及靶向治疗方面的研究进展。更多还原

【Abstract】 Acute myeloid leukemia(AML) is a kind of hematological malignancy originating from the cumulative genetic variation of hematopoietic stem/progenitor cells. It is more common in adults, with high incidence rate and mortality. Due to the high genetic heterogeneity of AML, the overall treatment prognosis is still not optimistic. With the evolution of high-throughput sequencing technology, the imbalance of histone acetylation modification has been revealed as the one of epigenetic variation to be the key genetic factor driving the development of AML. In recent years,targeted therapy of specific inhibitors regulating histone acetylation modification has been widely used and studied,which plays a non-negligible role in the occurrence and intervention of various tumors including AML. Therefore, this article reviews and prospects the current research progress of histone acetylation modification in the development and targeted therapy of AML.更多还原